Cargando…

Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates

INTRODUCTION: Sarcoidosis is an incurable, chronic granulomatous disease primarily involving the lungs and lymph nodes of unknown aetiology, treated with non-specific anti-inflammatory/immunosuppressive drugs. Persistently symptomatic patients worsen with a disabling, potentially fatal clinical cour...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Lary A, Smith, Prudence, SenGupta, Dhruba J, Prentice, Jennifer L, Sandin, Ramon L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884606/
https://www.ncbi.nlm.nih.gov/pubmed/24366580
http://dx.doi.org/10.1136/bmjopen-2013-004065
_version_ 1782298615947984896
author Robinson, Lary A
Smith, Prudence
SenGupta, Dhruba J
Prentice, Jennifer L
Sandin, Ramon L
author_facet Robinson, Lary A
Smith, Prudence
SenGupta, Dhruba J
Prentice, Jennifer L
Sandin, Ramon L
author_sort Robinson, Lary A
collection PubMed
description INTRODUCTION: Sarcoidosis is an incurable, chronic granulomatous disease primarily involving the lungs and lymph nodes of unknown aetiology, treated with non-specific anti-inflammatory/immunosuppressive drugs. Persistently symptomatic patients worsen with a disabling, potentially fatal clinical course. To determine a possible infectious cause, we correlated in a case-control study the clinical information with the presence of bacterial DNA in sarcoidosis mediastinal lymph nodes compared with control lymph nodes resected during cancer surgery. METHODS: We retrospectively studied formalin-fixed, paraffin-embedded, mediastinal lymph nodes from 30 patients with sarcoidosis and 30 control patients with lung cancer. Nucleic acids were extracted from nodes, evaluated by ribosomal RNA PCR for bacterial 16S ribosomal DNA and the results were sequenced and compared with a bacterial sequence library. Clinical information was correlated. RESULTS: 11/30 (36.7%) of lymph nodes from patients with sarcoidosis had detectable bacterial DNA, significantly more than control patient lymph nodes (2/30, 6.7%), p=0.00516. At presentation, 19/30 (63.3%) patients with sarcoidosis were symptomatic including all patients with detectable bacterial DNA. Radiographically, there were 18 stage I and 12 stage II patients. All stage II patients were symptomatic and 75% had PCR-detectable bacteria. After a mean follow-up of 52.8±32.8 months, all patients with PCR-detectable bacteria in this series were persistently symptomatic requiring treatment. DISCUSSION: 36.6% of patients with sarcoidosis had detectable bacterial DNA on presentation, all of these patients were quite symptomatic and most were radiographically advanced stage II. These findings suggest that bacterial DNA-positive, symptomatic patients have more aggressive sarcoidosis that persists long term and might benefit from antimicrobial treatment directed against this presumed chronic granulomatous infection.
format Online
Article
Text
id pubmed-3884606
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38846062014-01-08 Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates Robinson, Lary A Smith, Prudence SenGupta, Dhruba J Prentice, Jennifer L Sandin, Ramon L BMJ Open Respiratory Medicine INTRODUCTION: Sarcoidosis is an incurable, chronic granulomatous disease primarily involving the lungs and lymph nodes of unknown aetiology, treated with non-specific anti-inflammatory/immunosuppressive drugs. Persistently symptomatic patients worsen with a disabling, potentially fatal clinical course. To determine a possible infectious cause, we correlated in a case-control study the clinical information with the presence of bacterial DNA in sarcoidosis mediastinal lymph nodes compared with control lymph nodes resected during cancer surgery. METHODS: We retrospectively studied formalin-fixed, paraffin-embedded, mediastinal lymph nodes from 30 patients with sarcoidosis and 30 control patients with lung cancer. Nucleic acids were extracted from nodes, evaluated by ribosomal RNA PCR for bacterial 16S ribosomal DNA and the results were sequenced and compared with a bacterial sequence library. Clinical information was correlated. RESULTS: 11/30 (36.7%) of lymph nodes from patients with sarcoidosis had detectable bacterial DNA, significantly more than control patient lymph nodes (2/30, 6.7%), p=0.00516. At presentation, 19/30 (63.3%) patients with sarcoidosis were symptomatic including all patients with detectable bacterial DNA. Radiographically, there were 18 stage I and 12 stage II patients. All stage II patients were symptomatic and 75% had PCR-detectable bacteria. After a mean follow-up of 52.8±32.8 months, all patients with PCR-detectable bacteria in this series were persistently symptomatic requiring treatment. DISCUSSION: 36.6% of patients with sarcoidosis had detectable bacterial DNA on presentation, all of these patients were quite symptomatic and most were radiographically advanced stage II. These findings suggest that bacterial DNA-positive, symptomatic patients have more aggressive sarcoidosis that persists long term and might benefit from antimicrobial treatment directed against this presumed chronic granulomatous infection. BMJ Publishing Group 2013-12-21 /pmc/articles/PMC3884606/ /pubmed/24366580 http://dx.doi.org/10.1136/bmjopen-2013-004065 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Respiratory Medicine
Robinson, Lary A
Smith, Prudence
SenGupta, Dhruba J
Prentice, Jennifer L
Sandin, Ramon L
Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
title Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
title_full Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
title_fullStr Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
title_full_unstemmed Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
title_short Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
title_sort molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
topic Respiratory Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884606/
https://www.ncbi.nlm.nih.gov/pubmed/24366580
http://dx.doi.org/10.1136/bmjopen-2013-004065
work_keys_str_mv AT robinsonlarya molecularanalysisofsarcoidosislymphnodesformicroorganismsacasecontrolstudywithclinicalcorrelates
AT smithprudence molecularanalysisofsarcoidosislymphnodesformicroorganismsacasecontrolstudywithclinicalcorrelates
AT senguptadhrubaj molecularanalysisofsarcoidosislymphnodesformicroorganismsacasecontrolstudywithclinicalcorrelates
AT prenticejenniferl molecularanalysisofsarcoidosislymphnodesformicroorganismsacasecontrolstudywithclinicalcorrelates
AT sandinramonl molecularanalysisofsarcoidosislymphnodesformicroorganismsacasecontrolstudywithclinicalcorrelates